AI decision support for clot-dissolving treatment in acute ischemic stroke
Tests an AI tool to guide clot-dissolving treatment in adults with acute stroke.
Plain-language title generated from the registry record
Registry title: Artificial Intelligence Support for Stroke
Key facts
- Where
- Changsha, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a new ischemic stroke who reached a primary hospital in China within 24 hours of symptom onset. It tests an AI tool that supports the decision about clot-dissolving treatment.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Acute ischemic stroke, with onset (last known well) less than 24 hours ago. A CT or MRI scan must rule out bleeding in the brain.
- Earlier treatment
- People who already received intravenous thrombolysis at another hospital cannot join.
Main reasons for not taking part
- Taking part in another drug or device trial
- Pregnant women
- Already had intravenous thrombolysis at another hospital
- Decision on reperfusion treatment already made at another hospital, transferred here only for follow-up or rehabilitation
Read by machine on 9 November 2026.
Where in China
- Liuyang Jili HospitalChangsha, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Capital Medical University
- Trial code
- NCT07785492
- Record updated
- 27 August 2026
- Original description
This study investigates whether an AI-assisted decision support tool, compared with standard care, increases the proportion of acute ischemic stroke patients receiving intravenous thrombolysis within 24 hours of symptom onset at a primary hospital in China, while also evaluating its impact on clinical outcomes, treatment timelines, and safety.Read full original descriptionShow less
Artificial Intelligence-Assisted Decision Support for Intravenous Thrombolysis in Acute Ischemic Stroke at Basic Hospitals in China (ASSIST)
This study investigates whether an AI-assisted decision support tool, compared with standard care, increases the proportion of acute ischemic stroke patients receiving intravenous thrombolysis within 24 hours of symptom onset at a primary hospital in China, while also evaluating its impact on clinical outcomes, treatment timelines, and safety.
Inclusion: Age ≥18 years; Clinical diagnosis of acute ischemic stroke; Onset time (last known well) <24 hours; CT or MRI examination excluding intracerebral hemorrhage; Signed informed consent by the patient or a legally authorized representative.
Exclusion: Currently participating in another interventional clinical trial related to drugs or devices; Has received intravenous thrombolysis at another hospital; Has completed a definitive reperfusion therapy decision at another hospital and is transferred to this hospital solely for follow-up observation or rehabilitation; Pregnant women.